This cable, written on 23 January 2007, summarizes the proceedings of a video conference between US government officials and Hong Kong government officials that took place on 12 January 2007 with respect to ACTA and subsequent conversations between the Hong Kong government and the US consulate in Hong Kong. Continue Reading
On 2 November 2005, Ambassador Kevin Moley wrote the following entitled, “NOT A GOOD IDEA – WIPO PROPOSAL ON AVIAN INFLUENZA AND INTELLECTUAL PROPERTY RIGHTS” after meeting with Rita Hayes, Deputy Director General WIPO, to discuss a proposed WIPO-hosted meeting of a high-level advisory group for intellectual property and avian flu.
On December 21, 2007, the U.S. Consul General for São Paulo, Thomas White, wrote a cable titled: MICROSOFT SEES GOB ATTACKS AGAINST IPR. The cable was classified by James Story, the Econ/Pol Chief.
 |
| Ambassador Clifford Sobel (photo from Wikimedia) |
Wikileaks has published 28 cables, dated July 13, 2004 to February 9, 2010, from the US Embassy in Wellington, New Zealand that mention pharmaceuticals (See list here: /node/1231)
One of the cables discusses in detail the efforts of the New Zealand government to prevent pharmaceutical products that are sold in New Zealand from being parallel traded into the U.S. market. There are several interesting points made in the cable. Here are a few highlights:
From KEI staff review of Wikileaks cables (/wikileaks)
From September 19, 2005 to January 15, 2010, the US Department of State sent dozens of cables from Manila reporting on disputes in the Philippines regarding IPR and the pricing of pharmaceutical drugs. Much of the U.S. advocacy in the Philippines was done in close cooperation with Pfizer.
September 2, 2011
From KEI staff review of Wikileaks cables (/wikileaks)
On August 30, 2011, Wikileaks published a December 19, 2005 cable written by Daniel Rubinstein. The cable illustrates the degree to which the U.S. Department of State monitors the implementation of the Jordan-US FTA agreement, as regards disputes over rules on data exclusivity.